期刊文献+

趋化因子受体CCR_5反义RNA在真核细胞中的表达 被引量:1

Construction of recombinant vectors expressing antisense RNA to CCR_5 and expression in eukaryotic cells
原文传递
导出
摘要 目的 构建趋化因子受体CCR5反义RNA真核表达载体并获取重组假病毒颗粒以用于抗HIV 1研究。方法 用RT PCR法从健康人外周血单个核细胞 (PBMCs)中获得趋化因子受体CCR5翻译起始区的基因片段 ,并以正、反两个方向定向插入到真核表达载体pLXSN上。重组载体用脂质体转染剂 (lipofectAMINE)转染PA317包装细胞 ,抗 G418克隆的细胞上清经逆转录后用荧光定量PCR(FQ PCR)测定假病毒滴度 ,进一步感染NIH 3T3细胞。结果 CCR5正、反义RNA的真核表达载体 ,经PA317细胞包装形成的假病毒颗粒已成功地感染NIH 3T3细胞 ,目的基因在该细胞中得到整合与表达。结论 从PBMCs中获得的趋化因子受体CCR5基因片段通过逆转录病毒载体可转移至真核细胞中并得到表达 ,为进一步研究CCR5反义RNA的抗HIV Objective To construct recombinant vector expressing antisense RNA to CCR 5 in eukaryotic cells and obtain recombinant pseudovirus,which will be used to block HIV-1 infection.Methods The DNA fragment targeted against the initional part of CCR 5 mRNA translation was amplified by using RT-PCR from peripheral blood mononuclear cells (PBMCs) and cloned into retroviral vector pLXSN,then transfected into packaging cell(PA317)with lipofectAMINE. After 2-3 weeks selecting with G418,the pseudovirion in the survival cell's supernatant was detected with RT-PCR(FQ),then was used to infect NIH/3T3 cell. Results The psuedovirion packed from expression vector of sense/antisense RNA to CCR 5 had infected NIH/3T3 cell successfully. The vector had incorporated into its genome and transcripted into RNA. Conclusion The gene fragment of antisense RNA to CCR 5 could be obtained from PBMCs and transfected into eukaryotic cell with retroviral vector. The results made a great foundation for studying its inhibiting effect on HIV-1 infection.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2002年第1期52-54,共3页 Chinese Journal of Experimental and Clinical Virology
关键词 趋化因子受体 载体 假病毒 HIV-1感染 Receptor,chemotactic factors Vector Pseudovirion
  • 相关文献

参考文献4

  • 1Liu R,Paxton WA,Choe S,et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection.Cell,1996,86:367-377.
  • 2Quillent C,Oberlin E,Braun J,et al. HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet,1998,351:14-18.
  • 3Zagury D,Lachgar A,Chams V,et al. C-C chemokines,pivotal in protection against HIV type 1 infection.Proc Natl Acad Sci U S A,1998,95:3857-3861.
  • 4Mosier DE,Picchio GR,Gulizia RJ,et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR\-4-using variants.J Virol,1999,73:3544-3550.

同被引文献4

  • 1Larry O Arthur,Julian W,Bess jr,et al.Cellular proteins bound to immunodeficiency viruses:implications for Pathogenesis and vaccines.Science 1992,258:1935-1938.
  • 2Galea P,Contel C Le,Chermann JC,et al.Identification of a biological marker of resistance to AIDS progress.Cell Pharmacol.AIDS Sci,1996,3:311-316.
  • 3Galea P,Contel C Le,Chermann JC.A novel epitope R7V common to all HIV-1 isolates is recogniged by neutralizing IgG found in HIV-infected patients and neutralization of HIV isolates by HIV patient IgG directed to a viral-associated epitope.12th World AIDS Conference,Geneva.Switzerland,1998.
  • 4王福生,陈菊梅.HIV-1感染、致病机理和人体CCR5、CCR2等基因多态性之间的相互关系研究进展[J].中国性病艾滋病防治,2000,6(1):58-60. 被引量:7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部